Document is current

Article History

Received: 11 May 2021

Accepted: 5 August 2022

First Online: 6 September 2022

Competing interests

: C.P., G.M.W., J.L.G., and G.I.S. declare no Competing Non-Financial Interests but the following Competing Financial Interests: C.P. is employed by Bayer Pharmaceuticals. G.M.W. has received research funding from Merck & Co. and Glaxo Smith Kline. She also holds a patent entitled, “Pin1 as a marker for abnormal cell growth,” with royalties paid from R&D Systems and Cell Signaling Technology, and a pending patent entitled, “Compositions and methods for the treatment of proliferative diseases.” J.L.G. is a consultant for GlaxoSmithKline (GSK), Codagenix, Verseau, Kymera and Array BioPharma and receives sponsored research support from GSK, Array BioPharma and Eli Lilly. G.I.S. has received research funding from Eli Lilly, Merck KGaA/EMD-Serono, Merck, and Sierra Oncology. He has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA/EMD-Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros, Zentalis and CytomX Therapeutics. In addition, he holds a patent entitled, “Dosage regimen for sapacitabine and seliciclib,” also issued to Cyclacel Pharmaceuticals, and a pending patent, entitled, “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition,” together with Liam Cornell. The remaining authors declare no Competing Financial or Non-Financial Interests.